iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Twice-Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
 
 
  Reported by Jules Levin
Presented at the American Transplant Congress, May 1822, 2013, Seattle, Washington
The 13th Joint Annual Congress of the American Society of Transplant Surgeons and The American Society of Transplantation
 
Robert S. Brown, Jr., MD, MPH1; Mark W. Russo, MD2; Josh Levitsky, MD3; Kimberly A. Brown, MD4; Robert J. Fontana, MD5; Hugo Vargas, MD6; Eric Yoshida, MD7; Mohammad Bsharat, PhD8; Raymond Rubin, MD8 1Columbia University, New York, NY, USA; 2Carolinas Medical Center, Charlotte, NC, USA; 3Northwestern University, Chicago, IL, USA; 4Henry Ford Hospital, Detroit, MI, USA; 5University of Michigan, Ann Arbor, MI, USA; 6Mayo Clinic, Scottsdale, AZ, USA; 7University of British Columbia, Vancouver, British Columbia, CAN; 8Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA

HCV1.gif

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

HCV8.gif

HCV9.gif

HCV10.gif

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org